Christiane Drechsler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christiane Drechsler has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Christoph Wanner
Department of Medicine 1, Divisions of Nephrology and Cardiology University Hospital Würzburg Würzburg Germany
6 shared publications- Christoph Wanner
Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany
5 shared publications Vera Krane
¶Institute for Epidemiology and Biostatistics, University of Wuerzburg, Wuerzburg Germany
5 shared publications- Stefan Pilz
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
4 shared publications Winfried März
10 Synlab Services GmbH, Mannheim, Germany 11 Mannheim Institute of Public Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany 12 Clinical Institute of Medical and Chemical Laboratory Diagnostics Medical University of Graz, Graz, Austria
4 shared publicationsEberhard Ritz
Division of Nephrology, Department of Medicine , University Hospital Heidelberg , Heidelberg , Germany
3 shared publications
Latest Publications
- Open Access
- 1 October 2014
- Published by Elsevier in Atherosclerosis
- Vol. 236 (2) , 263-269
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients
- 1 October 2014
- Published by Elsevier in Atherosclerosis
- Vol. 236 (2) , 263-269
Open AccessPregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients
- Open Access
- 19 October 2013
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (2) , 289-295
Potential role of vitamin D deficiency on Fabry cardiomyopathy
Patients with Fabry disease frequently develop left ventricular (LV) hypertrophy and renal fibrosis. Due to heat intolerance and an inability to sweat, patients tend to avoid exposure to sunlight. We hypothesized that subsequent vitamin D deficiency may contribute to Fabry cardiomyopathy. This study investigated the vitamin D status and its association with LV mass and adverse clinical symptoms in patients with Fabry disease. 25‐hydroxyvitamin D (25[OH]D) was measured in 111 patients who were genetically proven to have Fabry disease. LV mass and cardiomyopathy were assessed by magnetic resonance imaging and echocardiography. In cross‐sectional analyses, associations with adverse clinical outcomes were determined by linear and binary logistic regression analyses, respectively, and were adjusted for age, sex, BMI and season. Patients had a mean age of 40 ± 13 years (42 % males), and a mean 25(OH)D of 23.5 ± 11.4 ng/ml. Those with overt vitamin D deficiency (25[OH]D ≤ 15 ng/ml) had an adjusted six fold higher risk of cardiomyopathy, compared to those with sufficient 25(OH)D levels >30 ng/ml (p = 0.04). The mean LV mass was distinctively different with 170 ± 75 g in deficient, 154 ± 60 g in moderately deficient and 128 ± 58 g in vitamin D sufficient patients (p = 0.01). With increasing severity of vitamin D deficiency, the median levels of proteinuria increased, as well as the prevalences of depression, edema, cornea verticillata and the need for medical pain therapy. In conclusion, vitamin D deficiency was strongly associated with cardiomyopathy and adverse clinical symptoms in patients with Fabry disease. Whether vitamin D supplementation improves complications of Fabry disease, requires a randomized controlled trial.
- 19 October 2013
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (2) , 289-295
Open AccessPotential role of vitamin D deficiency on Fabry cardiomyopathy
Patients with Fabry disease frequently develop left ventricular (LV) hypertrophy and renal fibrosis. Due to heat intolerance and an inability to sweat, patients tend to avoid exposure to sunlight. We hypothesized that subsequent vitamin D deficiency may contribute to Fabry cardiomyopathy. This study investigated the vitamin D status and its association with LV mass and adverse clinical symptoms in patients with Fabry disease. 25‐hydroxyvitamin D (25[OH]D) was measured in 111 patients who were genetically proven to have Fabry disease. LV mass and cardiomyopathy were assessed by magnetic resonance imaging and echocardiography. In cross‐sectional analyses, associations with adverse clinical outcomes were determined by linear and binary logistic regression analyses, respectively, and were adjusted for age, sex, BMI and season. Patients had a mean age of 40 ± 13 years (42 % males), and a mean 25(OH)D of 23.5 ± 11.4 ng/ml. Those with overt vitamin D deficiency (25[OH]D ≤ 15 ng/ml) had an adjusted six fold higher risk of cardiomyopathy, compared to those with sufficient 25(OH)D levels >30 ng/ml (p = 0.04). The mean LV mass was distinctively different with 170 ± 75 g in deficient, 154 ± 60 g in moderately deficient and 128 ± 58 g in vitamin D sufficient patients (p = 0.01). With increasing severity of vitamin D deficiency, the median levels of proteinuria increased, as well as the prevalences of depression, edema, cornea verticillata and the need for medical pain therapy. In conclusion, vitamin D deficiency was strongly associated with cardiomyopathy and adverse clinical symptoms in patients with Fabry disease. Whether vitamin D supplementation improves complications of Fabry disease, requires a randomized controlled trial.
- Open Access
- 10 October 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 219
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover. Here, we assessed the potential association of sclerostin with the development of coronary artery (CAC) and aortic valve calcifications (AVC) in haemodialysis (HD) patients.
- 10 October 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 219
Open AccessRelationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover. Here, we assessed the potential association of sclerostin with the development of coronary artery (CAC) and aortic valve calcifications (AVC) in haemodialysis (HD) patients.
- Open Access
- 22 March 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 67
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients.
- 22 March 2013
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 67
Open AccessPredicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients.
- 1 March 2013
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 8 (3) , 452-458
Low Plasma α-Tocopherol Concentrations and Adverse Clinical Outcomes in Diabetic Hemodialysis Patients
Summary: Background and objectives: Trials with the antioxidant vitamin E have failed to show benefit in the general population. Considering the different causes of death in ESRD, this study investigated the association between plasma concentrations of α-tocopherol and specific clinical outcomes in diabetic hemodialysis patients. Design, settings, participants, & measurements: In 1046 diabetic hemodialysis patients (participants of the German Diabetes and Dialysis Study), α-tocopherol was measured in plasma by reversed-phase HPLC. By Cox regression analyses, hazard ratios were determined for prespecified end points according to baseline plasma α-tocopherol levels: sudden death (n=134), myocardial infarction (n=172), stroke (n=89), combined cardiovascular events (n=398), fatal infection (n=107), and all-cause mortality (n=508). Results: Patients had a mean age of 66±8 years, and mean plasma α-tocopherol level was 22.8±9.6 µmol/L. Levels of α-tocopherol were highly correlated to triglycerides (r=0.63, Pstroke=1.56, 95% confidence interval=0.75–3.25; hazard ratiomortality=1.22, 95% confidence interval=0.89–1.69, respectively). There was no association between α-tocopherol and myocardial infarction, sudden death, or infectious death. Conclusions: Plasma α-tocopherol concentrations were not independently associated with cardiovascular outcomes, infectious deaths, or all-cause mortality in diabetic hemodialysis patients. The lack of association can partly be explained by a confounding influence of malnutrition, which should be considered in the planning of trials to reduce cardiovascular risk in dialysis patients.
- 1 March 2013
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 8 (3) , 452-458
Low Plasma α-Tocopherol Concentrations and Adverse Clinical Outcomes in Diabetic Hemodialysis Patients
Summary: Background and objectives: Trials with the antioxidant vitamin E have failed to show benefit in the general population. Considering the different causes of death in ESRD, this study investigated the association between plasma concentrations of α-tocopherol and specific clinical outcomes in diabetic hemodialysis patients. Design, settings, participants, & measurements: In 1046 diabetic hemodialysis patients (participants of the German Diabetes and Dialysis Study), α-tocopherol was measured in plasma by reversed-phase HPLC. By Cox regression analyses, hazard ratios were determined for prespecified end points according to baseline plasma α-tocopherol levels: sudden death (n=134), myocardial infarction (n=172), stroke (n=89), combined cardiovascular events (n=398), fatal infection (n=107), and all-cause mortality (n=508). Results: Patients had a mean age of 66±8 years, and mean plasma α-tocopherol level was 22.8±9.6 µmol/L. Levels of α-tocopherol were highly correlated to triglycerides (r=0.63, Pstroke=1.56, 95% confidence interval=0.75–3.25; hazard ratiomortality=1.22, 95% confidence interval=0.89–1.69, respectively). There was no association between α-tocopherol and myocardial infarction, sudden death, or infectious death. Conclusions: Plasma α-tocopherol concentrations were not independently associated with cardiovascular outcomes, infectious deaths, or all-cause mortality in diabetic hemodialysis patients. The lack of association can partly be explained by a confounding influence of malnutrition, which should be considered in the planning of trials to reduce cardiovascular risk in dialysis patients.
- Open Access
- 4 December 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (8) , 578-587
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
Sudden cardiac death is common and accounts largely for the excess mortality of patients on maintenance dialysis. It is unknown whether aldosterone and cortisol increase the incidence of sudden cardiac death in dialysis patients. We analysed data from 1255 diabetic haemodialysis patients participating in the German Diabetes and Dialysis Study (4D Study). Categories of aldosterone and cortisol were determined at baseline and patients were followed for a median of 4 years. By Cox regression analyses, hazard ratios (HRs) were determined for the effect of aldosterone, cortisol, and their combination on sudden death and other adjudicated cardiovascular outcomes. The mean age of the patients was 66 ± 8 years (54% male). Median aldosterone was 200 pg/mL had a significantly higher risk of sudden death (HR: 1.69; 95% CI: 1.06–2.69) compared with those with an aldosterone 200 pg/mL) and high cortisol (>21.1 µg/dL) levels increased the risk of sudden death in striking contrast to patients with low aldosterone (<15 pg/mL) and low cortisol (<13.2 µg/dL) levels (HR: 2.86, 95% CI: 1.32–6.21). Furthermore, all-cause mortality was significantly increased in the patients with high levels of both hormones (HR: 1.62, 95% CI: 1.01–2.62). The joint presence of high aldosterone and high cortisol levels is strongly associated with sudden cardiac death as well as all-cause mortality in haemodialysed type 2 diabetic patients. Whether a blockade of the mineralocorticoid receptor decreases the risk of sudden death in these patients must be examined in future trials.
- 4 December 2012
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (8) , 578-587
Open AccessAldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
Sudden cardiac death is common and accounts largely for the excess mortality of patients on maintenance dialysis. It is unknown whether aldosterone and cortisol increase the incidence of sudden cardiac death in dialysis patients. We analysed data from 1255 diabetic haemodialysis patients participating in the German Diabetes and Dialysis Study (4D Study). Categories of aldosterone and cortisol were determined at baseline and patients were followed for a median of 4 years. By Cox regression analyses, hazard ratios (HRs) were determined for the effect of aldosterone, cortisol, and their combination on sudden death and other adjudicated cardiovascular outcomes. The mean age of the patients was 66 ± 8 years (54% male). Median aldosterone was 200 pg/mL had a significantly higher risk of sudden death (HR: 1.69; 95% CI: 1.06–2.69) compared with those with an aldosterone 200 pg/mL) and high cortisol (>21.1 µg/dL) levels increased the risk of sudden death in striking contrast to patients with low aldosterone (<15 pg/mL) and low cortisol (<13.2 µg/dL) levels (HR: 2.86, 95% CI: 1.32–6.21). Furthermore, all-cause mortality was significantly increased in the patients with high levels of both hormones (HR: 1.62, 95% CI: 1.01–2.62). The joint presence of high aldosterone and high cortisol levels is strongly associated with sudden cardiac death as well as all-cause mortality in haemodialysed type 2 diabetic patients. Whether a blockade of the mineralocorticoid receptor decreases the risk of sudden death in these patients must be examined in future trials.
- 29 December 2011
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (7) , 693-701
Lipoprotein‐associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis
Eur J Clin Invest 2012; 42 (7): 693–701 Background Lipoprotein‐associated phospholipase A2 (LpPLA2) is a lipoprotein‐bound enzyme involved in inflammation and atherosclerosis. In a post hoc analysis of a controlled trial with atorvastatin in patients with type 2 diabetes (T2D) on haemodialysis, we examined the association between baseline and change by measuring baseline LpPLA2 activity on cardiovascular events (CVE) and mortality. Methods and results LpPLA2 activity was available of 1202 patients at baseline and 6 months after randomisation from 1255 patients in the German Diabetes Dialysis Study. During the 4‐year follow‐up, 445 patients (37%) suffered from CVE and 583 patients (49%) died. The highest quartile of LpPLA2 activity (≥615 U/L) was associated with elevated risk for CVE [HR 1·35 (1·02–1·87); P = 0·035]. This association was mainly driven by the placebo group [HR 1·51 (1·01–2·25); P = 0·046]. Receiver‐operating characteristics analysis revealed that including LpPLA2 activity in an already adjusted model increased the area under the curve (AUC) for CVE from 0·586 (0·553–0·620) to 0·632 (0·599–0·664; P = 0·020) and for death from 0·704 (0·674–0·733) to 0·708 (0·679–0·737; P = 0·026). In atorvastatin‐treated patients, the decrease in LpPLA2 was associated with reduced fatal risk [HR per standard deviation 0·74 (0·62–0·90); P = 0·002], an effect not seen in the placebo group. In contrast, those patients in the placebo group presenting a > 25% decrease in LpPLA2 activity (n = 33) had a more than doubled risk of dying [HR 2·48 (1·56–3·95); P < 0·001]. Conclusion LpPLA2 activity is predictive for cardiovascular outcome and total mortality. Reducing LpPLA2 by atorvastatin was associated with reduced mortality in patients with T2D on haemodialysis.
- 29 December 2011
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (7) , 693-701
Lipoprotein‐associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis
Eur J Clin Invest 2012; 42 (7): 693–701 Background Lipoprotein‐associated phospholipase A2 (LpPLA2) is a lipoprotein‐bound enzyme involved in inflammation and atherosclerosis. In a post hoc analysis of a controlled trial with atorvastatin in patients with type 2 diabetes (T2D) on haemodialysis, we examined the association between baseline and change by measuring baseline LpPLA2 activity on cardiovascular events (CVE) and mortality. Methods and results LpPLA2 activity was available of 1202 patients at baseline and 6 months after randomisation from 1255 patients in the German Diabetes Dialysis Study. During the 4‐year follow‐up, 445 patients (37%) suffered from CVE and 583 patients (49%) died. The highest quartile of LpPLA2 activity (≥615 U/L) was associated with elevated risk for CVE [HR 1·35 (1·02–1·87); P = 0·035]. This association was mainly driven by the placebo group [HR 1·51 (1·01–2·25); P = 0·046]. Receiver‐operating characteristics analysis revealed that including LpPLA2 activity in an already adjusted model increased the area under the curve (AUC) for CVE from 0·586 (0·553–0·620) to 0·632 (0·599–0·664; P = 0·020) and for death from 0·704 (0·674–0·733) to 0·708 (0·679–0·737; P = 0·026). In atorvastatin‐treated patients, the decrease in LpPLA2 was associated with reduced fatal risk [HR per standard deviation 0·74 (0·62–0·90); P = 0·002], an effect not seen in the placebo group. In contrast, those patients in the placebo group presenting a > 25% decrease in LpPLA2 activity (n = 33) had a more than doubled risk of dying [HR 2·48 (1·56–3·95); P < 0·001]. Conclusion LpPLA2 activity is predictive for cardiovascular outcome and total mortality. Reducing LpPLA2 by atorvastatin was associated with reduced mortality in patients with T2D on haemodialysis.
- 1 October 2011
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 58 (4) , 599-607
Wasting and Sudden Cardiac Death in Hemodialysis Patients: A Post Hoc Analysis of 4D (Die Deutsche Diabetes Dialyse Studie)
- 1 October 2011
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 58 (4) , 599-607
Wasting and Sudden Cardiac Death in Hemodialysis Patients: A Post Hoc Analysis of 4D (Die Deutsche Diabetes Dialyse Studie)
- Open Access
- 3 June 2011
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 11 (1) , 86
Understanding competing risks: a simulation point of view
Competing risks methodology allows for an event-specific analysis of the single components of composite time-to-event endpoints. A key feature of competing risks is that there are as many hazards as there are competing risks. This is not always well accounted for in the applied literature.
- 3 June 2011
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 11 (1) , 86
Open AccessUnderstanding competing risks: a simulation point of view
Competing risks methodology allows for an event-specific analysis of the single components of composite time-to-event endpoints. A key feature of competing risks is that there are as many hazards as there are competing risks. This is not always well accounted for in the applied literature.
- 31 January 2010
- Published by Elsevier in Atherosclerosis
- Vol. 208 (1) , 197-202
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus
- 31 January 2010
- Published by Elsevier in Atherosclerosis
- Vol. 208 (1) , 197-202
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus